연구동향 분석
박사

Bioanalytical method development for small and macromolecules using liquid chromatography-tandem mass spectrometry, and their application to pharmacokinetic study = 액체크로마토그래프탠덤질량분석기를 이용한 저분자 빛 고분자 물질의 분석법 개발 및 약동학에의 적용

정종우 2020년

논문상세정보
인용/피인용
' Bioanalytical method development for small and macromolecules using liquid chromatography-tandem mass spectrometry, and their application to pharmacokinetic study = 액체크로마토그래프탠덤질량분석기를 이용한 저분자 빛 고분자 물질의 분석법 개발 및 약동학에의 적용' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • Bioanalysis
  • Pharmacokinetics
  • Validation
  • lcms/ms
  • quantification
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
742 0

0.0%

' Bioanalytical method development for small and macromolecules using liquid chromatography-tandem mass spectrometry, and their application to pharmacokinetic study = 액체크로마토그래프탠덤질량분석기를 이용한 저분자 빛 고분자 물질의 분석법 개발 및 약동학에의 적용' 의 참고문헌

  • functions as an E2-dependent ubiquitin ? protein ligase and promotes the degradation of the synaptic vesicle-associated protein , CDCrel-1
    97 ( 24 ) :13354-9 . '' [2000]
  • brain distribution , and plasma protein binding of the antiepileptic drug lacosamide in rats
    34 ( 12 ) :2059-64 . '' [2011]
  • associated factor ? 1 mediates chemotherapeutic ? induced apoptosis via death effector filament formation
    115 ( 3 ) :412-8 . '' [2005]
  • al. , Pharmacokinetics of enzalutamide , an anti-prostate cancer drug , in rats
    38 ( 11 ) :2076-82 . '' [2015]
  • al. , Familial Parkinson disease gene product , parkin , is a ubiquitin-protein ligase .
    25 ( 3 ) :302-5 . '' [2000]
  • al. , Extracellular superoxide dismutase deficiency exacerbates pressure overload ? induced left ventricular hypertrophy and dysfunction
    51 ( 1 ) :19-25 . '' [2008]
  • a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade ,
    109 ( 24 ) :9629-34 . '' [2012]
  • Vyndaqel : EPAR-Product Information.
  • Trypsin cleaves exclusively C-terminal to arginine and lysine residues ,
    3 ( 6 ) :608-14 . '' [2004]
  • Transthyretin quaternary and tertiary structural changes facili-tate misassembly into amyloid ,
    50:161-81 . '' [1997]
  • Theoretical considerations of a ¡°well-stirred¡± model and a ¡°parallel tube¡± model . Influence of hepatic blood flow , plasma and blood cell binding , and the hepatocellular enzymatic activity on hepatic drug clearance
    5 , 625-53. ,5 ( 6 ) :625-53 . '' [1977]
  • The structure of human extracellular copper ? zinc superoxide dismutase at 1.7 A resolution : insights into heparin and collagen binding ,
    1 ; 388 ( 2 ) :310-26 . '' [2009]
  • The pathway by which the tetrameric protein trans-thyretin dissociates
    44 ( 47 ) :15525-33 . '' [2005]
  • The discovery of inhibitors of Fas-mediated cell death pathway using the combined computational method
    23 ( 18 ) :5155-64 . '' [2013]
  • Synthesis and biological evaluation of 3-substituted-benzofuran-2-carboxylic esters as a novel class of ischemic cell death inhibitors
    20 ( 22 ) :6362-5 . '' [2010]
  • Superoxide dismutases : role in redox signaling , vas-cular func-tion , and diseases
    15 ( 6 ) :1583-606 . '' [2011]
  • Superoxide dismutase 3 controls adaptive immune responses and contributes to the inhibition of ovalbumin-induced allergic airway inflammation in mice
    17 ( 10 ) :1376-92 . '' [2012]
  • Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC−MS/MS
    75 ( 13 ) :3019-30 . '' [2003]
  • Sleep Attacks in Patients With Parkinson 's Disease on Dopaminergic Medications : A Systematic Review
    1 ( 4 ) :307-316 . '' [2014]
  • Senile systemic amyloidosis presenting with heart failure : aComparison with lightChain
    165 ( 12 ) :1425-9 . '' [2005]
  • S. Method and apparatus for monitoring andCounteracting excess brain electrical energy to prevent epileptic seizures and the like
    [1974]
  • Role of superoxide dismutase 3 in skin inflammation ,
    67 ( 2 ) :81-7 . '' [2012]
  • Quantitative determination of enzalutamide , an anti-prostateCancer drug , in rat plasma using liquidChromatography ? tandem mass spectrometry , and its application to a pharmacokinetic study
    28 ( 8 ) :1112-7 . '' [2014]
  • Proteolytic activity of pseudotrypsin ,
    16 ( 4 ) :291-295 . '' [1971]
  • Protein misfolding in Alzheimer¡¯s and Parkinson¡¯s disease : genetics and molecular mechanisms
    23 ( 5 ) :957-76 . '' [2002]
  • Progress report on new antiepileptic drugs : A summary of the Twelfth EilatConference ( EILAT XII )
    [2015]
  • Prediction of missedCleavage sites in tryptic peptides aids protein identification in proteomics
    6 ( 1 ) :399-408 . '' [2007]
  • Point Mutations ( Thr240Arg and Ala311Stop ) in the Parkin Gene
    249 ( 3 ) :754-8 . '' [1998]
  • Physiological parameters in laboratory animals and humans .
    10 ( 7 ) :1093-5 . '' [1993]
  • Pharmacokinetics of lurasidone , a novel atypical anti-psychotic drug ,
    41 ( 12 ) :1100-7 . '' [2011]
  • Parkin ubiquitinates the ¥á-synuclein ? interacting protein , synphilin-1 : implications for Lewy body formation in Parkinson disease
    7 ( 10 ) :1144-50 . '' [2001]
  • Parkin mutations and susceptibility alleles in late ? onset Parkinson 's disease
    53 ( 5 ) :624-9 . '' [2003]
  • Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity .
    37 ( 5 ) :735-49 . '' [2003]
  • Parkin disease : a phenotypic study of a large case series
    126 ( Pt 6 ) :1279-92 '' [2003]
  • Parkin binds to ¥á/¥â tubulin and increases their ubiquitination and degradation .
    23 ( 8 ) :3316-24 . '' [2003]
  • Parkin Localizes to the Lewy Bodies of Parkinson Disease and Dementia with Lewy Bodies
    160 ( 5 ) :1655-67 . '' [2002]
  • Molecular pathways of neurodegeneration in Parkinson 's disease
    302 ( 5646 ) :819-22 . '' [2003]
  • Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis
    5 ( 1 ) :1-25 . '' [2016]
  • Mass Spectrometry Principles and Applications Third Edition
    [2007]
  • Lewy bodies and parkinsonism in families with parkin mutations
    50 ( 3 ) :293-300 . '' [2001]
  • K. Guideline on Nonclinical Evaluation of Pharmaceuticals for Permission and Clinical trials
    '' [2012]
  • Internal standards in the quantitative determination of protein biopharmaceuticals using liquid chromatography coupled to mass spectrometry
    [2012]
  • IPEP : an in silico tool to examine proteolytic peptides for mass spectrometry
    24 ( 23 ) :2801-2 . '' [2008]
  • Human Fas-associated factor 1 interacts with heat shock protein 70 and negatively regulates chaperone activity .
    280 ( 9 ) :8125-33 . '' [2005]
  • Histopathology of incidental findings in beagles used in toxicity studies .
    25 ( 1 ) :103-34 . '' [2012]
  • High-Performance Liquid Chromatography ( HPLC ) and High-Performance Liquid Chromatography ? Mass Spectrometry ( LC-MS ) , BIOANALYSIS OF PHARMACEUTICALS
  • Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease .
    60 ( 5 ) :796-801 . '' [2003]
  • Fridovich I. , Superoxide dismutase : the first twenty years
    5 ( 5-6 ) :363-9 . ''
  • Fibril in senile systemic amyloi-dosis is derived from normal transthyretin
    87 ( 7 ) :2843-5 . '' [1990]
  • Fas-associated factor 1 , FAF1 , is a member of Fas death-inducing signaling complex
    27 ; 278 ( 26 ) :24003-10 . '' [2003]
  • Familial-associated mutations differentially disrupt the solubility , localization , binding and ubiquitination properties of parkin
    14 ( 17 ) :2571-86 . '' [2005]
  • Familial amyloid polyneuropathy
    10 ( 12 ) :1086-97 . '' [2011]
  • FAF1 , plays a key role in the dopaminergic neurodegeneration .
    22 ( 8 ) :1558-73 . '' [2013]
  • Extracellular superoxide dismutase in biology and medicine
    35 ( 3 ) :236-56 . '' [2003]
  • Extracellular superoxide dismutase and its role in cancer
    [2017]
  • Etiology and pathogenesis of Parkinson 's disease
    22:123-44 . '' [1999]
  • Epileptic seizures and epilepsy : definitions proposed by the International League Against Epilepsy ( ILAE ) and the International Bureau for Epilepsy ( IBE )
    46 ( 4 ) :470-2 . '' [2005]
  • Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer , Drug Des Devel Ther
    7 : 875 ? 881 . '' [2013]
  • Enhancement of potency and stability of human extracellular superoxide dismutase ,
    48 ( 2 ) :91-6 . '' [2015]
  • Effect of wild-type or mutant Parkin on oxidative damage , nitric oxide , antioxidant defenses , and the proteasome
    277 ( 32 ) :28572-7 . '' [2002]
  • Development of new clean-up method for UPLC ? MS/MS analysis of leuprolide
    47 , 531-540 . '' [2017]
  • Development of a second-generation antiandrogen for treatment of advanced prostate cancer
    324 ( 5928 ) :787-90 . '' [2009]
  • Development and validation of a liquid chromatography-tandem mass spectrometry method for the assay of tafamidis in rat plasma : Application to a pharmacokinetic study in rats
    [2017]
  • Design and synthesis of fluorescent and biotin tagged probes for the study of molecular actions of FAF1 inhibitor
    26 ( 4 ) :1169-72 . '' [2016]
  • D. The clinical impact of new antiepileptic drugs after a decade of use in epilepsy
    50 ( 1-2 ) :21-32 . '' [2002]
  • Bioanalytical approaches to analyzing peptides and proteins by LC ? MS/MS , Bioanalysis
    3 ( 12 ) :1379-97 . '' [2011]
  • Bioanalysis of bio therapeutic proteins and peptides : immunological or MS approach ?
    4 ( 8 ) :857-60 . '' [2012]
  • Benzoxazoles as transthyretin amyloid fibril inhibitors : synthesis , evaluation , and mechanism of action
    42 ( 24 ) :2758-61 . '' [2003]
  • Aragon-Ching JB. , Metastatic Castration-Resistant Prostate Cancer : Critical Review of Enzalutamide .
    [2013]
  • Antitumour activity of MDV3100 in castration-resistant prostate cancer : a phase 1-2 study .
    375 ( 9724 ) :1437-46 . '' [2010]
  • 85 FDA, M3 (R2) nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. Available from: URL : https://www.fda.gov/media/71542/download
  • 63 Schlossmacher, MG, Shimura, H, Parkinsons Disease. in: Patterson, C., Cyr, DM., (Eds.), Ubiquitin-Proteasome Protocols. Humana Press, Totowa, NJ, p. 351-69.
  • 61 Parkinson, J., An Essay on the Shaking Palsy. J Neuropsychiatry Clin Neurosci. 2002 Spring;14(2):223-36
  • 57 Astellas, Product monograph. Available from: URL : http://www.cmsastellas.ca/uploads/pdf/Xtandi_PM_EN-Approved.pdf.
  • 55 Astellas, Full prescribing information. Available from: URL : http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203415lbl.pdf.
  • 47 Rowland M., Physiologically-Based Pharmacokinetic (PBPK) Modeling and Simulations: Principles, Methods, and Applications in the Pharmaceutical Industry, CPT Pharmacometrics Syst Pharmacol. 2013 Jul 10;2:e55.
  • 46 Houston JB, Carlile DJ., Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metab Rev. 1997 Nov;29(4):891-922.
    29 ( 4 ) :891-922 . '' [1997]
  • 38 US.FDA, Guidance for Industry, Bioanalytical Methods Validation, 2013.
  • 3 J©ªrgensen M, Kall MA., Regulated Bioanalysis and Guidelines, BIOANALYSIS OF PHARMACEUTICALS; 2015. p.283-303.
  • 23 European Medicines Agency, Guideline on bioanalytical method validation, Available from:URL: http://www.ema.europa.eu/docs/en_GB/document _library/Scientific_guideline/2011/08/WC500109686.pdf (accessed 15 March 2018).
  • 22 US. FDA, Guidance for Industry, Bioanalytical Methods Validation, Available from:URL: https://www.fda.gov/downloads/drugs/guidances/ucm368 107.pdf (accessed 15 March 2018).
  • 2012 FDA drug approvals
    12 , 87-90 . '' [2013]
  • 16 Brodie MJ, Shorvon SD, Canger R, Halasz P, Johannessen S, Thompson P., Commission on European Affairs: appropriate stand-ards of epilepsy care across Europe, Epilepsia. 1997 Nov;38(11):1245-50.
    38 ( 11 ) :1245-50 . '' [1997]
  • 14 European Medicines Agency, Guideline on bioanalytical method validation, Available from:URL: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf; 2011.
  • 13 US.FDA, Guidance for Industry, Bioanalytical Methods Validation, Available from:URL: http://www.fda.gov/cder/guidance/4252fnl.htm; 2001.
  • 11:185 ? 186
    [2012]